Mumbai, India (CU)_ Glenmark pharmaceuticals introduced a nasal spray in India for the treatment of adult patients with Covid-19 illness. FabiSpray, a Nitric Oxide Nasal Spray, was launched in collaboration with the Canada-based pharmaceutical business SaNOtize Research & Development Corp.
The Mumbai-based pharma business gained manufacturing and marketing authorisation for Nitric Oxide Nasal Spray from the drug regulator of India, the Drugs Controller General of India (DCGI), under an expedited approval procedure. According to the official statement, “Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94 per cent in 24 hours and 99 percent in 48 hours. Nitric Oxide Nasal Spray (NONS) was safe and well-tolerated in Covid-19 patients. Glenmark to market NONS under the brand name FabiSpray”.
FabiSpray eradicates the Covid-19 virus from the upper respiratory tract. According to the business, the Nitric Oxide Nasal is sprayed over the nasal mucosa, forming a physical and chemical barrier to fight the virus. The statement claims that the spray will prevent the infection from incubating and spreading to the lungs.
According to Robert Crockart’s statement, Glenmark Pharmaceuticals Ltd.’s chief commercial officer, “This reaffirms our commitment of providing yet another safe and effective antiviral treatment for Covid-19, and we are confident that it will offer patients a much needed and timely therapy option”. In July 2021, the firm reached an exclusive long-term strategic relationship with SaNOtize of Canada to manufacture and commercialize the nasal spray. Additionally, the spray will also be marketed to other Asian markets, including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste, and Vietnam.
In the meantime, the country recorded 71,365 new cases in the past 24 hours, bringing the total infection count to 4,24,10,976. The mortality rate has risen to 505,279 people. Moreover, according to the statistics, the number of active cases has declined below 9,00,000 mark, while the caseload has decreased to 8,92,828.
